General description

A cell-permeable oxadiazolyl-quinolinecarboxamide that is shown to selectively suppress STAT3, but not STAT1, STAT5a, or STAT5b, DNA binding activity in nuclear extract from IL-6-stimulated MDA-MB-468 cells (by 74% at 50 µM) and prevent IL-6-stimulated STAT3 dimerization in HEK293 cells (by 50% and 99%, respectively, at 74 and 100 µM), as well as inhibit the expression of STAT3 target genes, c-myc, cyclin D1, and survivin, both in cultures in vitro (effective conc. 50 µM) and in SCC3-derived tumors in mice in vivo (160 mg/kg/day; p.o.).

A cell-permeable oxadiazolyl-quinolinecarboxamide that is shown to selectively suppress STAT3, but not STAT1, STAT5a, or STAT5b, DNA binding activity and prevent IL-6-stimulated STAT3 dimerization in HEK293 cells (by 99% at 100 µM), as well as inhibit the expression of STAT3 target genes both in cultures in vitro (effective conc. 50 µM) and in SCC3-derived tumors in mice in vivo (160 mg/kg/day; p.o.).

Legal Information

CALBIOCHEM is a registered trademark of Merck KGaA, Darmstadt, Germany

Other Notes

Ashizawa, T., et al. 2011. Int. J. Oncol.38, 1245,Matsuno, K., et al. 2010. ACS Med. Chem. Lett.1, 371.

Packaging

25 mg in Glass bottle

Packaged under inert gas

Warning

Toxicity: Standard Handling (A)